Global & Disaster Medicine» Blog Archive » Two potential drugs have shown a survival rate of as much as 90% in a clinical trial in the Democratic Republic of Congo (DRC).

Two potential drugs have shown a survival rate of as much as 90% in a clinical trial in the Democratic Republic of Congo (DRC).

October 20th, 2019

“…..The experimental treatments – REGN-EB3 and a monoclonal antibody called mAb114 – were both developed using antibodies from Ebola survivors.

They are now going to be offered to all patients in the DRC, according to US National Institute of Allergy and Infectious Diseases…..”

Medscape

“……The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended approval of the V920 Ebola Zaire vaccine (Ervebo, Merck ), the first vaccine to protect against the Ebola virus disease caused by Zaire Ebola virus in at-risk adults aged 18 years or older…..”

This entry was posted on Sunday, October 20th, 2019 at 3:57 am and is filed under Ebola .
You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

Global & Disaster Medicine

Two potential drugs have shown a survival rate of as much as 90% in a clinical trial in the Democratic Republic of Congo (DRC).

Categories

Recent Posts

Archives

Admin